Can people with type 1 diabetes take Wegovy for weight loss?

The misconception worth correcting first: 'Wegovy is for weight loss, so anyone can use it for that'

A lot of people arrive at this question assuming that because Wegovy is licensed for weight management rather than diabetes, the diabetes-related cautions do not apply. That is not how it works. The STEP 1 trial (the pivotal study that secured Wegovy's weight-management licence, published in the New England Journal of Medicine) excluded people with type 1 diabetes entirely. So did the other trials in the STEP programme. When a medicine's licensing trials exclude a population, it means there is no robust evidence that it is safe or effective in that group, and no regulator has assessed it for them.

Semaglutide lowers blood glucose as part of how it works, and our page on semaglutide for weight loss in non-diabetics explains why that mechanism matters differently depending on whether you have diabetes. For someone managing type 1 diabetes with insulin, that is not a side note. It changes the insulin arithmetic directly. Eating less because your appetite has dropped means fewer carbohydrates, which means the insulin dose calculated before starting treatment may become too high. Hypoglycaemia (low blood sugar) is the result, and in type 1 diabetes it can be serious.

That is the core clinical concern, and it is why most prescribers, including our own, would not initiate Wegovy in a person with type 1 diabetes without specialist diabetes input. The NHS medicines guidance on semaglutide makes clear it is not recommended alongside insulin without careful clinical oversight.

What is actually known, and what remains uncertain

There is some early research exploring GLP-1 medicines in type 1 diabetes, mostly in people who also have insulin resistance or obesity. Some small studies have shown modest weight and glucose benefits. None of this evidence is large enough, long enough, or consistent enough to have changed prescribing guidelines in the UK.

What is not uncertain: the risks are real. Hypoglycaemia, diabetic ketoacidosis (DKA) and the complexity of adjusting insulin around a medicine that dramatically changes how much you eat all require active, specialist-level monitoring. These are not risks that an online pharmacy consultation is set up to manage safely. The broader picture of how Wegovy interacts with type 1 diabetes management is covered in more depth on our page about type 1 diabetes and Wegovy.

For comparison, type 2 diabetes sits differently. Wegovy's licence explicitly includes people with type 2 diabetes as a qualifying weight-related condition, and the STEP 2 trial ran specifically in that group. If that is your situation, the picture looks quite different, and our page on whether diabetics can take Wegovy for weight loss explains what the evidence shows for people in that position. Our separate page on Wegovy for people with type 2 diabetes goes into further detail on that specific group.

Who should type 1 diabetics talk to about weight management?

The honest answer is your diabetes specialist team, not an online weight-loss service. Weight management in type 1 diabetes is a genuinely specialist area. Some people are under a structured diabetes clinic that has experience with GLP-1 medicines off-label; some are not. Your diabetes consultant or diabetologist is the person who can look at your HbA1c, your insulin regime, your CGM data if you wear one, and your weight-related health picture together.

If your GP practice has a diabetes-focused pharmacist or nurse, they are another route in. The NHS England guidance on weight-management injections sets out the clinical context for these medicines and reinforces why individual assessment matters so much. Practical weight-loss support (dietary changes, activity, behavioural support) is available through NHS services without the complexities of adding a prescription medicine.

At nume, our prescribers review every consultation personally. For someone with type 1 diabetes, that review would most likely result in a recommendation to seek specialist diabetes input rather than us prescribing Wegovy independently, and our page covering whether diabetics can take Wegovy walks through that clinical reasoning in full. That is not a limitation of our service; it is what responsible prescribing looks like. You can learn more about how our clinical team approaches complex cases on the clinical team page.

If Wegovy is not right for you right now, what are your options?

A few things worth knowing. First, weight management matters enormously in type 1 diabetes, it is not a vanity concern. Carrying excess weight increases insulin resistance even in people whose pancreas produces no insulin, which makes blood glucose harder to control and raises cardiovascular risk. So the clinical need is real, even if the route to addressing it is more complex.

Second, the landscape is changing. Research into GLP-1 medicines and type 1 diabetes is ongoing. Guidelines may evolve. Staying in contact with your diabetes team keeps you informed as that happens.

Third, for people without type 1 diabetes who are exploring semaglutide for weight loss, our Wegovy treatment page sets out the full picture, how it works, who qualifies, and how treatment through nume is structured. If you are unsure which treatment might suit your situation, the weight-loss overview is a good place to start. And if you want to explore whether you might be clinically suitable, a free consultation with our prescribers is the first step, no obligation, reviewed by a real clinician the same day.